Medicine Recommendations

Treatment of chemotherapy induced colitis

Crohn's disease
Ulcerative colitis

Treatment of chronic asthma in adults and children aged 12 years and over (NICE TA138) and in children under the age of 12 years (NICE TA131)

NICE TA131 - Inhaled corticosteroids for the treatment of chronic asthma in children under the age of 12 years

NICE TA138 - Inhaled corticosteroids for the treatment of chronic asthma in adults and in children aged 12 years and over

Peripheral vascular disease (NICE TA223)

NICE TA223 - Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease

Type 1 and type 2 diabetes mellitus

For the treatment of diabetes mellitus type 1 and 2 in adults

Type 2 diabetes

Type 1 diabetes

Treatment of adults with type 2 diabetes mellitus (T2DM) to improve glycaemic control, in combination with oral glucose-lowering medicinal products when these alone, or combined with basal insulin, do not provide adequate glycaemic control

Treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above

Type 1 and Type 2 diabetes mellitus

For biosimilars see Insulin glargine biosimilar (Abasaglar®)

Type 1 and Type 2 diabetes mellitus

Treatment of diabetes

Type 1 diabetes mellitus

Type 2 diabetes mellitus

Type 2 diabetes mellitus [in combination with metformin]

Type 1 and type 2 diabetes mellitus

Type 1 and type 2 diabetes mellitus

Treatment of diabetes mellitus in adults

Diabetes monitoring

Reason for decision: A specialist clinician or the clinician who oversees the patient’s diabetes care still needs to determine a patient’s eligibility. When a patient satisfies the eligibility criteria, ongoing supplies of sensors can now be prescribed by GPs. The initiating clinician must have received appropriate training on the initiation and use of flash glucose monitoring products and will supply the patient with a scanning device and sensors to cover the initial 2 weeks of use of flash glucose monitoring.